Refractory multiple myeloma
Clinical trials for Refractory multiple myeloma explained in plain language.
Never miss a new study
Get alerted when new Refractory multiple myeloma trials appear
Sign up with your email to follow new studies for Refractory multiple myeloma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered donor cells could outsmart relapsed myeloma
Cure Not yet recruitingThis trial tests whether a specially engineered donor stem cell transplant, called Orca-Q, can safely treat people with high-risk multiple myeloma that has returned or not responded to prior therapy. The transplant uses donor blood-forming cells and immune cells, with certain T c…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase 1 • Sponsor: University of California, Davis • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
New CAR t combo takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase 1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a One-Two drug punch beat back Hard-to-Treat myeloma?
Disease control Not yet recruitingThis early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one p…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase 1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
CAR-T breakthroughs come with infection risks – new study aims to decode them
Knowledge-focused Not yet recruitingThis study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC